Breast Cancer - Pipeline Review, H2 2015

Breast Cancer - Pipeline Review, H2 2015

Code: GMDHC6820IDB | Published: Dec-2015 | Pages: 2995 | Global Markets Direct
Price :
$2,500.00
USD

* Required Fields

$2,500.00

Details

Breast Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Breast Cancer - Pipeline Review, H2 2015, provides an overview of the Breast Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Breast Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Breast Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Breast Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
3-V Biosciences, Inc.
4SC AG
A&G Pharmaceutical, Inc.
A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc.
AbGenomics International, Inc.
Ability Pharma, SL
Acceleron Pharma, Inc.
Acetylon Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc.
Adaptimmune Limited
ADC Therapeutics Sarl
Aduro BioTech, Inc.
Advanced Cancer Therapeutics
Advanced Proteome Therapeutics Corporation
Advaxis, Inc.
Advenchen Laboratories, LLC
Aegis Therapeutics, LLC
Aeglea BioTherapeutics, Inc.
Aerpio Therapeutics, Inc.
Aeterna Zentaris Inc.
Affichem SA
Agilvax, Inc.
Aileron Therapeutics, Inc.
Alchemia Limited
Alethia Biotherapeutics Inc.
Almac Discovery Limited
Amarna Therapeutics B.V.
Ambrx, Inc.
Amgen Inc.
Ampio Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc.
AngioGenex, Inc.
Angion Biomedica Corp.
ANP Technologies, Inc.
AntiCancer, Inc.
Antigen Express, Inc.
Antoxis Limited
Aphios Corporation
arGEN-X BV
Armour Therapeutics Inc.
Arno Therapeutics, Inc.
ArQule, Inc.
Arrien Pharmaceuticals, LLC
Ascenta Therapeutics, Inc.
Ascentage Pharma Group Corporation, Ltd.
AskAt Inc.
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
Athenex, Inc.
ATLAB Pharma SAS
Atossa Genetics, Inc.
Aurigene Discovery Technologies Limited
Ausio Pharmaceuticals, LLC
Axelar AB
Azaya Therapeutics, Inc.
Basilea Pharmaceutica AG
Bavarian Nordic A/S
Bayer AG
BeiGene(Beijing) Co.,Ltd
BerGenBio AS
Beth Israel Deaconess Medical Center, Inc.
Bexion Pharmaceuticals, LLC.
Bio-Path Holdings, Inc.
BIOCAD
Biocon Limited
Bionomics Limited
Bionovis SA
BioNTech AG
Bioo Therapeutics
Biotecnol, Inc.
Biotest AG
Blirt S.A.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
BriaCell Therapeutics Corp.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Campus Technologies Freiburg GmbH
Cantex Pharmaceuticals, Inc.
CASI Pharmaceuticals Inc.
CEL-SCI Corporation
Celgene Corporation
Cellceutix Corporation
Celldex Therapeutics, Inc.
Cellectar Biosciences, Inc.
Celltrion, Inc.
Celsion Corporation
Ceronco Biosciences
Cerulean Pharma, Inc.
Champions Oncology, Inc.
ChemoCentryx, Inc.
China Grand Wuhan General Pharmaceutical Research Institute
Chipscreen Biosciences Ltd
Chugai Pharmaceutical Co., Ltd.
Clevexel Pharma SAS
Clovis Oncology, Inc.
CohBar, Inc.
Compliment Corporation
Corcept Therapeutics Incorporated
Cristal Therapeutics
Critical Outcome Technologies Inc.
Curadev Pharma Private Limited
Curadis GmbH
Curaxys, S.L.
CureFAKtor Pharmaceuticals, LLC
Curis, Inc.
Cyclacel Pharmaceuticals, Inc.
CytomX Therapeutics, Inc.
CZ BioMed Corp
Daiichi Sankyo Company, Limited
Debiopharm International S.A.
Deciphera Pharmaceuticals, LLC
DEKK-TEC, Inc.
DexTech Medical AB
Digna Biotech, S.L.
DiNonA Inc.
DNA Therapeutics S.A.
Dompe Farmaceutici S.p.A.
Dongkook Pharmaceutical Co., Ltd.
DormaTarg, Inc.
Dr. Reddys Laboratories Limited
Egenix, Inc.
EirGenix Inc.
Eisai Co., Ltd.
Eli Lilly and Company
EndoCeutics, Inc.
Endocyte, Inc.
EnGeneIC Ltd
Ensol Biosciences Inc.
EntreChem, S.L.
EOS Biosciences, Inc.
Epigen Biosciences, Inc.
Epirus Biopharmaceuticals, Inc.
Erytech Pharma SA
Esperance Pharmaceuticals, Inc.
Etubics Corporation
Eureka Therapeutics, Inc.
Evgen Pharma PLC
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
FibroStatin SL
FirstString Research, Inc.
Forendo Pharma Limited
Fortress Biotech, Inc.
G&E Herbal Biotechnology Co., Ltd.
G1 Therapeutics, Inc.
Galapagos NV
Galectin Therapeutics, Inc.
Galena Biopharma, Inc.
Galileo Research s.r.l.
Ganymed Pharmaceuticals AG
Genelux Corporation
Genenta Science s.r.l.
Genentech, Inc.
Genor BioPharma Co., Ltd.
Genoscience Pharma
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
Glycotope GmbH
Green Cross Corporation
GTx, Inc.
Halozyme Therapeutics, Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Heat Biologics, Inc.
HEC Pharm Co., Ltd.
Helix BioPharma Corp.
Hemispherx Biopharma, Inc.
Hetero Drugs Limited
Histogen, Inc.
Horizon Pharma Plc
Hospira, Inc.
Huabo Biopharm Co., Ltd.
Huperion Sarl
Hutchison MediPharma Limited
Ignyta, Inc.
Ildong Pharmaceutical Co., Ltd.
Immune Design Corp.
ImmuneXcite, Inc.
ImmunoFrontier, Inc.
ImmunoGen, Inc.
Immunomedics, Inc.
Immunophotonics Inc
Immunovaccine, Inc.
Immupharma Plc
IMPACT Therapeutics, Inc.
Imugene Limited
Inbiopro Solutions Pvt. Ltd.
Incanthera Ltd.
Incyte Corporation
Infinity Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc.
Intas Pharmaceuticals Ltd.
Intica Biomedical, Inc.
Invictus Oncology Pvt. Ltd.
Io Therapeutics, Inc.

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]


2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal


3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at cs@marketinforesearch.com.

CUSTOMERS WHO VIEWED THIS REPORT ALSO VIEWED

There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct